MétaCan
Menu
← Back to cohort
Record W2789736501 · doi:10.1093/ecco-jcc/jjx180.045

DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registry

2018· article· en· W2789736501 on OpenAlexaff
Dan Turner, Sibylle Koletzko, Harland S. Winter, Robert N. Baldassano, M Dubinsky, William A. Faubion, Jeffrey S. Hyams, Subra Kugathasan, Joel R. Rosh, J. C. Escher, Anne M. Griffiths, Jarosław Kierkuś, RK Russell, Graham Heap, Dilek Arikan, V Kuehnl, J Petersson, Anne Robinson, Frank M. Ruemmele

Bibliographic record

VenueJournal of Crohn s and Colitis · 2018
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsSickKids FoundationHospital for Sick ChildrenUniversity of Toronto
Fundersnot available
KeywordsMedicineInterquartile rangeAdalimumabInterimAdverse effectInterim analysisObservational studyClinical trialPediatricsInternal medicineDisease

Abstract

fetched live from OpenAlex

The 3-year safety and efficacy data of adalimumab (ADA) in children and adolescents with moderately to severely active Crohn’s disease (CD) enrolled in the IMAgINE 1 trial (N = 192; ADA exposure, 151.8 patient-years [PYs]) were previously reported (Faubion, et al. IBD 2017). ADA long-term safety and effectiveness is currently being assessed in the postmarketing observational registry, CAPE. Interim safety data are reported herein. CAPE is a non-interventional, multinational, registry designed to include up to 10 years of routine clinical practice data on paediatric patients (6–17 years) with moderately to severely active CD receiving ADA (Humira®) or immunomodulator (IMM) monotherapy (azathioprine, mercaptopurine, or methotrexate). For this interim analysis at 3 years (started August 29, 2014), adverse events (AEs) were monitored through May 31, 2017. AE rates were assessed as events per 100 PYs (E/100 PYs) of ADA and IMM exposure, respectively. Registry treatment-emergent AEs (TEAEs) were defined as any AE occurring from the first dose of ADA or IMM in the registry through the last dose plus 70 days (ADA) or 30 days (IMM) or up to cut-off. A total of 909 patients (ADA, N = 518; IMM, N = 391) were enrolled representing 378.8 and 328.2 PYs of exposure to ADA and IMM, respectively. 28 patients have withdrawn from the registry (ADA, n = 13; IMM, n = 15). At entry into CAPE, patient median (interquartile range) age was 15 (13–16) years and mean (SD) CD duration was 2.8 (2.46) years; the majority of patients are male (59%) and white (89%). TEAE incidence proportions and event rates per 100 PYs are shown in Table 1. The rates of AEs and serious AEs (SAEs) were lower than the rates reported in the IMAgINE clinical trials. The majority of SAEs were associated with underlying CD in both registry groups. The most common serious infection (n [%]) was abdominal abscess in the ADA registry group (3 [0.6]) and gastroenteritis in the IMM registry group (2 [0.5]). There were no TEAEs of opportunistic infection, tuberculosis, malignancy, or demyelinating disorders reported in either registry group. Three cases of worsening/new onset of psoriasis were reported in the ADA group. No pregnancies or deaths were reported. The safety of ADA observed in CAPE was comparable to its known benefit risk profile in children and adolescents with moderately to severely active CD, and no new safety signals were identified. Longer observation periods are needed to ascertain a more accurate risk of uncommon AEs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.014
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.044

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0080.014
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.005
GPT teacher head0.221
Teacher spread0.217 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and Colitis→Same topicInflammatory Bowel Disease→French-language works237,207→